




RealRate

PHARMACEUTICAL 2023

Vera Therapeutics Inc
Rank 279 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Vera Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vera Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 61% points. The greatest weakness of Vera Therapeutics Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 218%, being 27% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	125,698
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	25,600
Liabilities, Non-Current	3,831
Other Assets	5,686
Other Compr. Net Income	0
Other Expenses	1.0
Other Liabilities	25,096
Other Net Income	1,848
Other Revenues	0
Property and Equipment	51
Research and Development	68,993
Selling, General and Administrative Expense	21,910

Output Variable	Value in 1000 USD
Assets	131,435
Liabilities	54,527
Expenses	90,904
Revenues	0
Stockholders Equity	76,908
Net Income	-89,056
Comprehensive Net Income	-89,056
BaseVar	139,357
ECR before LimitedLiability	85%
Economic Capital Ratio	218%